Durata Therapeutics (DRTX) 10-K 14 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'Durata Therapeutics, Inc.	'	'
Entity Central Index Key	'0001544116	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	26,640,309	'
Entity Public Float	'	'	$87.60

Consolidated_Balance_Sheet

Consolidated Balance Sheet (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$36,853	$32,257
Short-term investments	22,880	13,094
Prepaid expenses and other current assets	3,367	5,844
Total current assets	63,100	51,195
Acquired in process research and development	15,292	15,292
Goodwill	5,811	5,811
Property and equipment, net	897	981
Restricted cash	1,147	852
Deferred charge	10,081	12,417
Other assets	3,816	'
Total assets	100,144	86,548
Current liabilities:	'	'
Accounts payable	5,275	8,618
Accrued expenses	7,116	10,602
Income taxes payable	1,609	2,281
Total current liabilities	14,000	21,501
Long-term debt	25,000	'
Non-current income tax payable	1,377	1,117
Contingent consideration	20,889	19,836
Other liabilities	299	222
Total liabilities	61,565	42,676
Commitments and contingencies (note 13)	'	'
Stockholders' equity:	'	'
Common stock, $0.01 par value; 125,000,000 shares authorized at December 31, 2013 and December 31, 2012, respectively; 26,625,749 and 18,360,459 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively	266	184
Preferred stock, $0.01 par value; 5,000,000 shares authorized at December 31, 2013 and December 31, 2012; no shares issued and outstanding at December 31, 2013 and 2012	'	'
Additional paid-in capital	207,754	150,988
Accumulated deficit during the development stage	-169,441	-107,300
Total stockholders' equity	38,579	43,872
Total liabilities and stockholders' equity	$100,144	$86,548

Consolidated_Balance_Sheet_Par

Consolidated Balance Sheet (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	26,625,749	26,625,749
Common stock, shares outstanding	18,360,459	18,360,459
Preferred Stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'

Consolidated_Statement_of_Oper

Consolidated Statement of Operations (USD $)	12 Months Ended			50 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Operating expenses:	'	'	'	'
Research and development expenses	$37,317	$51,695	$30,133	$124,161
General and administrative expenses	18,602	9,788	4,305	36,384
Acquisition related charges, net	1,053	1,097	1,121	9,597
Operating loss	56,972	62,580	35,559	170,142
Other (income) expense:	'	'	'	'
Interest expense	2,226	'	'	2,226
Loss on early extinguishment of debt	2,228	'	'	2,228
Interest income	-62	-41	-15	-121
Other income	-501	'	'	-501
Total other (income) expense	3,891	-41	-15	3,832
Loss before income tax expense (benefit)	60,863	62,539	35,544	173,974
Income tax expense (benefit)	1,278	0	-2,511	-4,533
Net loss	($62,141)	($62,539)	($33,033)	($169,441)
Net loss per common share-Basic and Diluted	($2.57)	($7.48)	($551.51)	'
Weighted-average common shares-Basic and Diluted	24,224,590	8,364,432	59,896	'

Consolidated_Statement_of_Chan

Consolidated Statement of Change in Stockholders' Equity (USD $)		Total	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Class A Preferred Stock [Member]
In Thousands, except Share data
Balance inception at Nov. 04, 2009		'	'	'	'	'	[1]
Balance inception, shares at Nov. 04, 2009		'	'	'	'	'
Issued under incentive stock programs		5	'	5	'	'
Issued under incentive stock programs, shares		'	15,625	'	'	'
Issuance of Series A convertible preferred stock		8,000	'	7,920	'	80	[1]
Issuance of Series A convertible preferred stock, shares	[1]	'	'	'	'	7,999,992
Stock based compensation expense		2	'	2	'	'
Net loss		-714	'	'	-714	'
Balance at Dec. 31, 2009		7,293	'	7,927	-714	80	[1]
Balance, shares at Dec. 31, 2009		'	15,625	'	'	7,999,992	[1]
Issued under incentive stock programs		7	'	7	'	'
Issued under incentive stock programs, shares		'	15,625	'	'	'
Issuance of Series A convertible preferred stock		5,198	'	5,146	'	52	[1]
Issuance of Series A convertible preferred stock, shares	[1]	'	'	'	'	5,197,945
Stock based compensation expense		328	'	328	'	'
Net loss		-11,014	'	'	-11,014	'
Balance at Dec. 31, 2010		1,812	'	13,408	-11,728	132	[1]
Balance, shares at Dec. 31, 2010		'	31,250	'	'	13,197,937	[1]
Issued under incentive stock programs		13	1	12	'	'
Issued under incentive stock programs, shares		'	31,250	'	'	'
Issuance of Series A convertible preferred stock		36,000	'	35,640	'	360	[1]
Issuance of Series A convertible preferred stock, shares	[1]	'	'	'	'	35,999,999
Stock based compensation expense		768	'	768	'	'
Net loss		-33,033	'	'	-33,033	'
Balance at Dec. 31, 2011		5,560	1	49,828	-44,761	492	[1]
Balance, shares at Dec. 31, 2011		'	62,500	'	'	49,197,936	[1]
Issuance of Series A convertible preferred stock		22,000	'	21,780	'	220	[1]
Issuance of Series A convertible preferred stock, shares	[1]	'	'	'	'	22,000,000
Stock based compensation expense		1,406	'	1,406	'	'
Net loss		-62,539	'	'	-62,539	'
Proceeds from stock options exercised		146	'	146	'	'
Proceeds from stock options exercised, shares		'	23,221	'	'	'
Conversion of Series A convertible preferred stock to common stock		6,000	97	6,615	'	-712	[1]
Conversion of Series A convertible preferred stock to common stock, shares		'	9,649,738	'	'	-71,197,936	[1]
Initial public offering, net		71,299	86	71,213	'	'
Initial public offering, shares		'	8,625,000	'	'	'
Balance at Dec. 31, 2012		43,872	184	150,988	-107,300	'
Balance, shares at Dec. 31, 2012		'	18,360,459	'	'	'
Stock based compensation expense		2,595	'	2,595	'	'
Net loss		-62,141	'	'	-62,141	'
Proceeds from stock options exercised		55	'	55	'	'
Proceeds from stock options exercised, shares		'	42,790	'	'	'
Issuance of common stock, net		53,660	82	53,578	'	'
Issuance of common stock, shares		'	8,222,500	'	'	'
Issuance of warrants to acquire common stock		437	'	437	'	'
Excess tax benefit on stock-based awards		101	'	101	'	'
Balance at Dec. 31, 2013		$38,579	$266	$207,754	($169,441)	'
Balance, shares at Dec. 31, 2013		'	26,625,749	'	'	'
[1]	Does not include the $6,000,000 portion of the preferred stock that was redeemable upon certain conditions by the holders. These shares along with the non-redeemable portion of the Series A convertible preferred stock were converted to common stock at the time of the initial public offering (see note 10, Stockholders' Equity and Stock Compensation).

Consolidated_Statement_of_Chan1

Consolidated Statement of Change in Stockholders' Equity (Parenthetical) (Class A Preferred Stock [Member], USD $)	Dec. 31, 2012
Class A Preferred Stock [Member]	'
Preferred stock redeemable upon certain conditions by the holders	$6,000,000

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	12 Months Ended			50 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Cash flows from operating activities:	'	'	'	'
Net loss	($62,141)	($62,539)	($33,033)	($169,441)
Adjustments to reconcile net loss to net cash used by operating activities:	'	'	'	'
Loss on early extinguishment of debt	2,228	'	'	2,228
Depreciation and amortization	253	15	'	267
Stock based compensation expense	2,595	1,406	780	5,124
Acquisition related charges, net	1,053	1,097	1,121	9,597
Non-cash interest expense	569	'	'	569
Deferred income taxes	-1,013	'	-2,511	-6,824
Changes in operating assets and liabilities:	'	'	'	'
Prepaid expenses and other current assets	3,799	-4,810	-948	-2,007
Contingent receivable	'	'	5,421	5,421
Deferred charge	2,336	-12,417	'	-10,081
Other assets	-610	'	'	-610
Accounts payable	-3,068	6,385	1,251	5,275
Accrued expenses	-4,643	9,233	561	5,958
Income taxes payable/receivable	-2,253	3,398	'	1,145
Other liabilities	77	222	'	299
Net cash used by operating activities	-60,818	-58,010	-27,358	-153,080
Cash flows from investing activities:	'	'	'	'
Acquisition of in process research and development	'	'	'	-10,000
Purchases of property and equipment	-445	-719	'	-1,164
Purchases of short-term investments	-29,888	-13,094	'	-42,982
Proceeds from sale of short term investments	20,000	'	'	20,000
Other investing activities	-291	-850	'	-1,141
Other assets	'	'	'	-40
Net cash used by investing activities	-10,624	-14,663	'	-35,327
Cash flows from financing activities:	'	'	'	'
Proceeds of issuance of Series A preferred stock	'	22,000	36,000	77,198
Proceeds from issuance of common stock, net	54,104	73,912	'	128,016
Payments for offering costs	-444	-2,613	'	-3,057
Proceeds from issuance of long-term debt	45,000	'	'	45,000
Payment of debt financing fees	-1,084	'	'	-1,084
Payment to retire long term debt	-21,694	'	'	-21,694
Proceeds from stock options exercised	55	146	'	201
Excess tax benefit on stock-based awards	101	'	'	101
Proceeds from receipt of contingent receivable	'	'	579	579
Net cash provided by financing activities	76,038	93,445	36,579	225,260
Net increase in cash	4,596	20,772	9,221	36,853
Cash and cash equivalents, beginning of year and period	32,257	11,485	2,264	'
Cash and cash equivalents, end of year and period	36,853	32,257	11,485	36,853
Non-cash financing activities:	'	'	'	'
Conversion of Series A Convertible Preferred Stock to common stock (shares)	'	77,197,936	'	77,197,936
Non-cash investing activities:	'	'	'	'
Capital expenditures included in current liabilities	'	277	'	'
Cash paid for interest	1,657	'	'	1,657
Cash paid for income taxes	$2,107	$9,800	'	$11,907

Nature_of_Business_Organizatio

Nature of Business, Organization and Liquidity	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Nature of Business, Organization and Liquidity	'
	-1	Nature of Business, Organization and Liquidity
	Durata Therapeutics, Inc. and subsidiaries (a development stage company) (the Company) is a Delaware corporation and has its principal place of business in Chicago, Illinois. The Company is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company was incorporated on November 4, 2009. In December 2009, the Company entered into an agreement with Pfizer Inc. (Pfizer) to acquire Vicuron Pharmaceuticals Inc. (Vicuron) (see note 6, Acquisitions – Milestone Payment).
	To date, the Company has not generated any revenues and has financed its operations primarily through private placements of its preferred stock, its initial public offering of its common stock in July 2012 (see note 10, Stockholders’ Equity and Stock Compensation), a secured debt financing completed in March 2013 and refinanced with a new lender in October 2013 (see note 9, Long-term Debt), and a public offering of its common stock in April 2013 (see note 10, Stockholders’ Equity and Stock Compensation). The Company expects to continue to incur significant expenses to seek marketing approval for dalbavancin, establish a commercial organization, conduct clinical trials for additional indications for dalbavancin (including osteomyelitis, diabetic foot infection and pneumonia), as well as new dosing strategies and formulations, and possibly other product candidates and manufacture product. The Company had a net loss of $62.1 million for the year ended December 31, 2013 and had a deficit accumulated during the development stage of $169.4 million from inception until December 31, 2013.
	Based on the Company’s existing cash and cash equivalents and short-term investments, the Company estimates that it has sufficient funding to sustain its operations through early 2015. The Company estimates that such funds will be sufficient to enable it to seek marketing approval in the United States and the European Union for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI), and, if approved, to commercially launch dalbavancin in the United States and possibly Western Europe, as well as explore the development of dalbavancin for additional indications and new dosing strategies and formulations. The Company has based this estimate on assumptions that may prove to be wrong, and it could use its available capital resources sooner than it currently expects.
	The Company also believes it has other financing alternatives available, including the incremental $15.0 million the Company is required to borrow from PDL BioPharma, Inc. (PDL) upon marketing approval of dalbavancin in the United States (see note 9, Long-term Debt), to fund additional activities until its operations generate adequate operating cash flows, which include additional equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company also has limited fixed commitments for uses of cash and has the intent and ability, if necessary, to delay or eliminate expenditures until adequate funding is available.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	-2	Summary of Significant Accounting Policies
		(a)	Basis of Presentation and Principles of Consolidation
	The consolidated financial statements of the Company are prepared on the accrual basis of accounting. All intercompany accounts and transactions have been eliminated.
		(b)	Use of Estimates
	The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.
		(c)	Development Stage Company
	The Company’s primary activities since inception have been organizing and staffing the Company, business planning, raising capital and acquiring and developing dalbavancin. Accordingly, the Company is considered to be in the “development stage” and has prepared the accompanying consolidated financial statements in accordance with the provisions of the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) No. 915, Accounting for Development Stage Entities.
		(d)	Cash and Cash Equivalents and Restricted Cash
	The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash resources principally in money market funds.
	Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted in the next twelve months, the restricted cash account is classified as current. Included within Restricted Cash on the Company’s December 31, 2013 and 2012 consolidated balance sheet are certificates of deposit for $1.1 million and $0.9 million, respectively, which are being held by a third party bank as collateral for the irrevocable letters of credit issued in connection with the Company’s two office leases (see note 13, Commitments and Contingencies).
		(e)	Financial Instruments
	The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is established that prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:
		Level 1:	Observable inputs such as quoted prices in active markets for identical assets or liabilities;
		Level 2:	Inputs other than the quoted prices included in Level 1 that are observable for the asset or liability either directly or indirectly; and
		Level 3:	Unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions.
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. See note 4, Financial Instruments, for additional information.
		(f)	Short-term Investments
	As of December 31, 2013 , cash equivalents and short-term investments consist of investments in money market accounts, federal agency bonds and corporate entity commercial paper and bonds that are classified as available-for-sale pursuant to ASC 320, Investments—Debt and Equity Securities. The Company classifies investments available to fund current operations as current assets on its balance sheet. Investments are classified as long-term assets on the balance sheet if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year. All of the Company’s investments are classified as current.
	The fair value of these securities is based on quoted prices for identical or similar assets. If a decline in the fair value is considered other-than-temporary the unrealized loss, if any, would be transferred from other comprehensive loss to the statement of operations. There were no charges taken for other-than-temporary declines in fair value of short-term investments during 2013. Realized gains and losses are determined using the specific identification method and are included in interest income in the statement of operations. Realized gains and losses recognized during the years ended December 31, 2013 and 2012 were immaterial.
	The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers its intent to sell, or whether it is more likely than not that the Company will be required to sell, the investment before recovery of the investment’s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and the duration of the impairment and changes in value subsequent to year end. As of December 31, 2013, there were no investments with a fair value that was lower than the amortized cost basis or any investments that had been in an unrealized loss position for a significant period. See note 4, Financial Instruments, for further information.
		(g)	Deferred Financing Costs
	The Company capitalizes certain legal, accounting and other fees that are directly associated with in-process debt and equity financings as current assets until such financings occur. In the case of an equity financing, after occurrence, these costs are recorded in equity, net of proceeds received. In the case of a debt financing, these costs are recorded as other assets and amortized to interest expense over the term of the debt.
	As of December 31, 2013, the Company recorded debt financing costs of $0.4 million in connection with the debt financing completed in October 2013. The debt financing costs recorded in connection with the debt financing completed in March 2013 were expensed at the time the debt was repaid (see Note 9, Long-term Debt, for more information). The Company also incurred offering costs of $0.4 million in connection with the public offering of its common stock that closed in April 2013. The debt financing costs are recorded in other assets on the consolidated balance sheet, net of accumulated amortization. The offering costs are recorded in equity as an offset to the proceeds received from the sale of the shares.
		(h)	Other Intangible Assets
	The Company had an acquired in-process research and development (IPR&D) intangible asset of $15.3 million as of December 31, 2013 and 2012. Acquired IPR&D intangible assets represent the right to develop, use, sell or offer for sale intellectual property that the Company has acquired with respect to processes that have not been completed. These assets are required to be classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until their processes are completed and the Company receives regulatory approval from a major market to allow for the commencement of commercial marketing activities. At that time, the Company will determine the useful life of the asset, reclassify the asset out of in-process research and development and begin amortization. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.
	If the associated research and development effort is abandoned, the related assets likely will be written-off and the Company will record a non-cash impairment loss on its consolidated statement of operations. Acquired in-process research and development assets which are determined to have had a decrease in fair value are adjusted to fair value with an impairment charge. Such assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment. Intangible assets with definite useful lives will be amortized to their estimated residual values over their estimated useful lives and reviewed for impairment if certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See note 8, Goodwill and Intangibles, for additional information.
		(i)	Goodwill
	Goodwill represents the excess of purchase price over fair value of net assets acquired in a business combination accounted for by the acquisition method of accounting and is not amortized, but subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment. The Company had goodwill of $5.8 million as of December 31, 2013 and 2012. See note 8, Goodwill and Intangibles, for additional information.
		(j)	Property and Equipment
	Property and equipment are recorded at cost, net of depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. The following table shows the estimated useful lives of the Company’s property and equipment:
	Classification		Estimated Useful Lives
	Leasehold improvements		Lesser of useful life or lease term
	Furniture and fixtures		5 years
	Information technology related		3-5 years
	Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized. Repairs and maintenance costs are expensed as incurred. See note 5, Property and Equipment, for additional information.
		(k)	Impairment of Long-Lived Assets
	Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
		(l)	Operating Leases
	Rent expense related to leases is recorded on a straight-line basis over the term of the lease, including any rent free periods. The difference between actual rent payments and straight-line rent expense is recorded as deferred rent and included in other liabilities in the accompanying consolidated balance sheet.
		(m)	Research and Development Costs
	Research and development costs are expensed as incurred and are primarily comprised of the following types of costs incurred in performing research and development activities:
		•		employee-related expenses, including salaries, benefits, travel and share-based compensation expense;
		•		external research and development expenses incurred under arrangements with third parties, such as contract research organizations (CROs), manufacturing organizations and consultants, including our scientific advisory board; and
		•		facilities and laboratory and other supplies.
		(n)	Income Taxes
	The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which the temporary differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained. See note 12, Income Taxes, for additional information.
		(o)	Share-Based Compensation
	The Company uses share-based compensation in the form of stock options and restricted stock. Compensation expense is recognized in the consolidated statement of operations based on the estimated fair value of the shares at grant date. Compensation cost to be recognized reflects an estimate of the number of shares expected to vest after taking into consideration an estimate of forfeiture. The fair values of stock option grants are estimated as of the date of grant using the Black-Scholes option valuation model. The fair value of option grants are based on the fair value of the Company’s common stock on the date of grant. See note 10, Stockholders’ Equity and Stock Compensation, for additional information.
		(p)	Warrant Accounting
	In connection with the loan agreement with Oxford Finance LLC, or Oxford, discussed in note 9, Long-term Debt, the Company granted warrants for the purchase of the Company’s common stock. The Company accounted for these common stock warrants in accordance with applicable accounting guidance provided in ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, as equity instruments based on the specific terms of the warrant agreements.
		(q)	Concentrations
	The Company maintains cash and cash equivalent balances with financial institutions which, at times, may exceed insurance limits established by the Federal Deposit Insurance Corporation. Management does not consider this to be a significant risk due to the long-standing reputation of these financial institutions.
	The Company has entered into agreements with a contract manufacturer to manufacture clinical and future commercial supplies of dalbavancin. The Company has also entered into an agreement with a contract manufacturer to supply the drug substance for dalbavancin in the form of injectable grade powder. The loss of either of these suppliers could have a material adverse effect upon the Company’s operations.

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Prepaid Expenses and Other Current Assets	'
	-3	Prepaid Expenses and Other Current Assets
	Prepaid expenses and other current assets consist of the following (in thousands):
			December 31,		December 31,
			2013		2012
	Income tax receivable		$	1,971	$	—
	Deferred tax asset			35		781
	Prepaid manufacturing fees (a)			665		4,550
	Prepaid insurance			262		353
	Other prepaid assets			381		98
	Other receivables			53		62
			$	3,367	$	5,844
	(a)	During 2012, the Company paid amounts to its primary manufacturer of active pharmaceutical ingredient for the production of validation batches that were produced in 2013.

Financial_Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2013
Investments All Other Investments [Abstract]	'
Financial Instruments	'
	-4	Financial Instruments
	The following table presents information about the Company’s financial assets that have been measured at fair value at December 31, 2013 and 2012, and indicates the fair value hierarchy of the valuation inputs used to determine such fair value (in thousands):
			2013
			Fair Value		Level 1		Level 2		Level 3
	Assets:
	Money market fund investments		$	27,156	$	27,156	$	—	$	—
	Available for sale securities:
	Federal agency bonds			14,847		14,847		—		—
	Corporate commercial paper			3,998		3,998		—		—
	Corporate bonds			4,035		4,035		—		—
	Total available for sale securities		$	22,880	$	22,880	$	—	$	—
	Liabilities:
	Contingent Liability		$	20,889	$	—	$	—	$	20,889
			2012
			Fair Value		Level 1		Level 2		Level 3
	Assets:
	Money market fund investments		$	30,537	$	30,537	$	—	$	—
	Available for sale securities:
	Federal agency bonds			8,090		8,090		—		—
	Corporate commercial paper			3,997		3,997		—		—
	Corporate bonds			1,007		1,007		—		—
	Total available for sale securities		$	13,094	$	13,094	$	—	$	—
	Liabilities:
	Contingent Liability		$	19,836	$	—	$	—	$	19,836
	Additional information for the Company’s recurring fair value measurements using significant unobservable inputs (Level 3 inputs) was follows (in thousands):
	Balance at December 31, 2011		$	18,739
	Contingent consideration expense			1,097
	Transfers in and/or out of Level 3			—
	Balance at December 31, 2012		$	19,836
	Contingent consideration expense			1,053
	Transfers in and/or out of Level 3			—
	Balance at December 31, 2013		$	20,889
	At December 31, 2013 and 2012, the balance of the contingent liability consideration, which reflects the fair value of the contingent milestone payment, was $20.9 million and $19.8 million, respectively. The Company’s contingent consideration is based on Level 3 inputs within the fair value hierarchy. Fair values determined based on Level 3 inputs use unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. The underlying probability of payment of the contingent liability was 85% and 80% as of December 31, 2013 and 2012, respectively. The increase in the probability was due to positive study data for both of the two most recently completed Phase 3 clinical trials.
	Certain financial instruments reflected in the consolidated balance sheets (for example, cash, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature.
	All available for sale securities have maturity dates less than one year. As of December 31, 2013, unrealized gains and losses on available for sale securities were immaterial.

Property_and_Equipment_Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment, Net	'
	-5	Property and Equipment, Net
	Property and equipment and related accumulated depreciation are as follows (in thousands):
			December 31,			December 31,
			2013			2012
	Furniture and fixtures		$	673		$	641
	Information technology related			348			226
	Leasehold improvements			143			129
				1,164			996
	Less: accumulated depreciation			(267	)		(15	)
	Property and equipment, net		$	897		$	981
	Depreciation expense was $0.3 million and $15,000 for the year ended December 31, 2013 and 2012, respectively.

Acquisitions_Milestone_Payment

Acquisitions - Milestone Payment	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisitions - Milestone Payment	'
	-6	Acquisitions – Milestone Payment
	In December 2009, the Company acquired the rights to dalbavancin through its acquisition of all of the outstanding shares of capital stock of Vicuron from Pfizer pursuant to a stock purchase agreement (Pfizer Agreement). The Company paid total upfront consideration of $10.0 million for the shares of Vicuron and the dalbavancin inventory to be used in research. In addition, upon the successful clinical development, regulatory approval and first commercial sale of dalbavancin, in the United States or one of five major European markets, the Company is required to pay Pfizer an additional milestone payment of $25.0 million. However, under the Company’s credit agreement with PDL discussed in note 9, Long-term Debt, the Company is prohibited from making any payment to Pfizer as long as amounts are outstanding under the Company’s credit agreement with PDL. Under the Pfizer Agreement, the Company, at its sole discretion, may elect to defer the milestone payment for a period of up to five years if it delivers to Pfizer a promissory note for the full amount of such milestone payment. Interest on the outstanding principal amount of the promissory note will accrue at a rate of 10% per annum, compounded annually.
	In addition, another contingent aspect of the acquisition related to the potential refund of $6.0 million of the initial purchase price. The Company completed an assessment of the probability of the successful clinical development, regulatory approval and commercial sale of dalbavancin in future periods and determined that a liability of $5.8 million should be recorded at December 11, 2009 to reflect the best estimate of additional cash consideration likely to be paid related to the potential $25.0 million milestone payment. The Company also recorded the fair value of a contingent asset of $0.6 million at December 11, 2009 based on the probability of receiving the potential refund from Pfizer of $6.0 million of the initial purchase price.
	Subsequent to the closing date of the acquisition, the Company measures the contingent consideration arrangements at fair value for each period with changes in fair value recognized in our statements of operations under acquisition related charges, net. Changes in fair value reflect new information about the acquired in process research and development asset and its progress toward approval, and the passage of time, and therefore ultimately the probability of achieving regulatory approval for dalbavancin (see note 4, Financial Instruments, for further information on this liability). Separately, the possibility of receiving the $6.0 million contingent asset was also reassessed as development efforts continued. The Company received the $6.0 million contingent receivable in March 2011. In the absence of new information, changes in fair value reflect only the passage of time as development work towards the achievement of the milestones progresses.

Other_Assets

Other Assets (Other Assets [Member])	12 Months Ended
	Dec. 31, 2013
Other Assets [Member]	'
Other Assets	'
	-7	Other Assets
	Other noncurrent assets consist of the following (in thousands):
			December 31,
			2013		2012
	Debt financing costs, net		$	419	$	—
	Deferred tax assets, net			1,629		—
	Manufacturing supplies			1,768		—
	Total other assets		$	3,816	$	—

Goodwill_and_Intangibles

Goodwill and Intangibles	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangibles	'
	-8	Goodwill and Intangibles
	The Company tests its goodwill for impairment annually as of December 31 each year unless indicators, events, or circumstances would require an immediate review. Goodwill is tested in accordance with ASU 2011-08, Intangibles—Goodwill and Other (Topic 350): Testing Goodwill for Impairment, or ASU 2011-08, which allows a company the option to assess qualitative factors to determine whether it is necessary to perform a two-step quantitative goodwill impairment test. Under ASU 2011-08, a company is not required to calculate the fair value of its reporting unit unless the company determines, based on that qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. There was no impairment of the Company’s goodwill as a result of impairment tests as of December 31, 2013, 2012 or 2011.
	The Company tests its indefinite lived intangible assets annually for impairment as of December 31 using ASU 2012-02, “Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment,” or ASU 2012-02. ASU 2012-02 allows a company the option to assess qualitative factors to determine whether it is necessary to perform a quantitative impairment test. Under ASU 2012-02, a company is not required to calculate the fair value of a given indefinite-lived intangible asset unless the company determines, based on that qualitative assessment, that it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. There was no impairment of the Company’s IPR&D asset as a result of impairment tests as of December 31, 2013, 2012 or 2011.

Longterm_Debt

Long-term Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Long-term Debt	'
	-9	Long-term Debt
	In March 2013, the Company and certain of its subsidiaries entered into a loan agreement with Oxford (the Oxford term loan), pursuant to which the Company’s wholly-owned Dutch subsidiaries borrowed an aggregate principal amount of $20.0 million.
	In connection with the Oxford term loan, the Company granted Oxford warrants for the purchase of 67,999 shares of the Company’s common stock at an exercise price of $8.68 per share. The warrants are exercisable for seven years from the date of issuance. The grant date fair value of the warrants was $6.42 per share as estimated using a Black-Scholes pricing model. In accordance with ASC 470-20-25-2, Debt Instruments with Detachable Warrants, the proceeds from the debt issuance have been allocated between the warrants and the debt instrument based on the relative fair value. The portion allocated to the warrants has been recorded as paid-in capital.
	On October 31, 2013, the Company and certain of its subsidiaries entered into a credit agreement with PDL (the PDL credit agreement), pursuant to which the Company’s wholly-owned Dutch subsidiaries borrowed an aggregate principal amount of $25.0 million (the First Tranche) and upon the satisfaction of certain conditions to funding set forth in the PDL credit agreement, will be required to borrow an additional aggregate principal amount of $15.0 million (the Second Tranche). The Company may also make a one-time election to borrow an additional aggregate principal amount of up to $30.0 million (the Delayed Draw) during the nine month period following the date on which the Company receives marketing approval of dalbavancin from the U.S. government (provided that such date, if it occurs at all, occurs on or prior to December 31, 2014) (the Second Tranche Milestone).
	The funding of the Second Tranche and the Delayed Draw are subject in each instance to the satisfaction of certain conditions set forth in the PDL credit agreement, including, without limitation, the continued accuracy of representations and warranties, no default or material adverse change having occurred, the execution and delivery of additional loan documents, if required, and the Second Tranche Milestone having occurred.
	Any amount borrowed under the credit agreement is guaranteed by the Company and certain of the Company’s subsidiaries. The loans and the guarantee obligations are secured by a lien on substantially all of the Company’s assets and all or substantially all of the assets of the Company’s subsidiaries (other than Durata Therapeutics Limited), as applicable, including the pledge of the equity interests in each of the Company’s direct and indirect subsidiaries to secure the applicable loan and guarantee obligations.
	The First Tranche bears interest at an annual rate equal to 14.00% until the Second Tranche Milestone occurs, if it occurs at all. Thereafter, each term loan bears interest at an annual rate equal to 12.75%. The credit agreement provides for interest-only payments payable quarterly in arrears through December 31, 2014, and payment of interest and principal in quarterly installments in the amounts specified in the PDL credit agreement starting on March 31, 2015 and continuing quarterly thereafter through September 30, 2018. The final maturity of the loan is October 31, 2018.
	The Company paid an origination fee to PDL when the Company entered into the credit agreement, which is included in deferred finance costs in other assets at December 31, 2013. At the Company’s option, the Company may elect to prepay all of the outstanding term loan plus any accrued interest, plus a prepayment penalty determined with respect to the principal amount of the term loan being prepaid. The credit agreement also provides for indemnification of PDL and the other lenders from time to time party to the credit agreement.
	The credit agreement also contains certain representations, warranties and covenants (including maintaining liquidity of at least $2 million) applicable to the Company and its subsidiaries. The credit agreement contains certain events of default. The obligations under the credit agreement and the other loan documents may, at PDL’s option, be accelerated upon the occurrence of certain events of default, and are automatically accelerated upon certain bankruptcy-related events of default.
	The net proceeds of the First Tranche were used to repay amounts outstanding under the Oxford loan agreement, including prepayment penalties and fees, and the remainder of the proceeds of the First Tranche has been used for general corporate purposes. Upon termination of the Oxford term loan, the Company recorded a loss on the early extinguishment of debt of $2.2 million, which consisted of the prepayment penalty, the unamortized debt discount and the unamortized debt issuance costs.
	At December 31, 2013, future payments of principal are due as follows (in thousands):
	Years ending December 31,
	2014		$	—
	2015			1,250
	2016			5,000
	2017			8,750
	2018			10,000
	Total long-term debt		$	25,000
	The fair value of the long-term debt at December 31, 2013, based upon current market rates, approximated carrying value.

Stockholders_Equity_and_Stock_

Stockholders' Equity and Stock Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stockholders' Equity and Stock Compensation	'
	-10	Stockholders’ Equity and Stock Compensation
		(a)	Common Stock
	On April 17, 2013, the Company closed a public offering of an aggregate of 8,222,500 shares of common stock at a public offering price of $7.00 per share, including 1,072,500 shares pursuant to the exercise by the underwriters of an over-allotment option. Net proceeds were approximately $54.1 million, after deducting underwriting discounts and commissions but prior to the payment of offering expenses by the Company.
	In July 2012, the Company closed the initial public offering of its common stock pursuant to a registration statement on Form S-1, as amended. The Company sold an aggregate of 8,625,000 shares of common stock under the registration statement at a public offering price of $9.00 per share, including 1,125,000 shares pursuant to the exercise by the underwriters of an over-allotment option. Net proceeds were approximately $73.9 million, after deducting underwriting discounts and commissions but prior to the payment of offering expenses by the Company. Upon closing the initial public offering, all the then outstanding shares of the Company’s Series A Convertible Preferred Stock were converted into 9,649,738 shares of common stock.
	In December 2009, the Company issued 62,500 shares of restricted common stock to an officer in return for services to be rendered over the effective vesting period. This award fully vested in January 2011.
	Also included in common stock at December 31, 2013 were 35,717 common shares issued upon exercise of options during the year ended December 31, 2013 and 14,670 shares of vested restricted stock. There are 5,569 restricted shares unvested as of December 31, 2013.
		(b)	Series A Convertible Preferred Stock
	Prior to completing its initial public offering, the Company issued and sold an aggregate of 77,197,936 shares of its Series A Convertible Preferred Stock that resulted in the Company receiving cash proceeds of $77,197,936. The proceeds were used for research and development and general working capital. In July 2012, upon closing its initial public offering, all the then outstanding shares of the Company’s convertible preferred stock were converted into 9,649,738 shares of common stock.
	In July 2012, the Company’s one-for-8.000 reverse stock split became effective, effectively changing the conversion price of the Series A Convertible Preferred Stock.
		(c)	Stock Incentive Plans
	The two stock incentive plans (Incentive Plans) described in this section are the pre-IPO stock incentive plan, as amended (the Incentive Plan), and the 2012 Stock Incentive Plan (2012 Plan). Prior to the Company’s initial public offering, the Company granted awards to eligible participants under the Incentive Plan. Following the initial public offering, the Company grants awards to eligible participants under the 2012 Plan.
	2012 Stock Incentive Plan (2012 Plan)
	In April 2012, the Company’s board of directors and stockholders approved the 2012 Plan. The 2012 Plan became effective immediately prior to the closing of the Company’s initial public offering. The 2012 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards of the Company to employees, consultants, officers and directors. As of December 31, 2013, the number of shares of the Company’s common stock reserved for issuance under the 2012 Plan was 107,783. This number may increase for the number of shares of the Company’s common stock subject to outstanding awards under the Company’s Incentive Plans, that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right. In addition, the 2012 Plan provides for an annual increase, to be added on the first day of fiscal year 2014 and each subsequent anniversary until the expiration of the 2012 Plan, equal to the lowest of 437,500 shares of the Company’s common stock, 2.75% of the number of shares of the Company’s common stock outstanding on the first day of the fiscal year or an amount determined by the board of directors.
	Pre-IPO Stock Incentive Plan (Incentive Plan)
	Upon the closing of its initial public offering, the Company ceased granting any awards under the Incentive Plan.
	The Incentive Plan provided for the granting of stock options and other stock awards of the Company to employees, consultants, officers and directors. General awards under the Incentive Plan consisted of a specified number of options awarded subject to the satisfaction of various vesting conditions determined and specified by the Company at the time of the award. In April 2012, the Company’s board of directors and stockholders approved an amendment to the Incentive Plan to increase the number of shares reserved for issuance under the Incentive Plan from 1,875,000 to 2,125,000.
	In April 2012, the Board resolved that all options granted under the Incentive Plan may be exercisable from the date of grant. If exercised prior to full vesting, restricted shares of common stock are issued and continue to vest in the same manner as the original options awarded. Upon termination of employment any unvested options or unvested restricted shares are immediately cancelled and available for future grant under the 2012 Plan, while vested options are exercisable for a defined period. The outstanding option grants at December 31, 2013 have a term of 10 years and generally vest over periods up to 4 years.
	Activity with respect to options was as follows:
			Options Outstanding								Exercisable Options
			Shares			Weighted			Weighted		Shares		Weighted
						average			average				average
						exercise			remaining				exercise
						price per			contractual				price per
						share			life (years)				share
	December 31, 2010			1,350,000		$	0.96			9.38		101,561	$	0.96
	Granted			160,000			1.68			—
	Forfeited or expired			—			—			—
	Exercised			—			—			—
	December 31, 2011			1,510,000		$	1.06			8.52		527,181	$	0.97
	Granted			730,309			7.73			—
	Forfeited or expired			63,188			4.94			—
	Exercised			38,642			3.78			—
	December 31, 2012			2,138,479		$	3.17			8.21		952,499	$	1.4
	Granted			649,238			7.98			—
	Forfeited or expired			100,114			6.06			—
	Exercised			35,717			1.69			—
	December 31, 2013			2,651,886		$	4.26			7.67		1,477,786	$	2.12
	The following table summarizes additional information regarding options outstanding and exercisable at December 31, 2013:
			Options Outstanding								Exercisable Options
			Number of			Weighted			Weighted		Number of		Weighted		Weighted
			options			average			average		options		average		average
			outstanding			remaining			exercise		exercisable		remaining		exercise
			at year end			contractual			price		at year end		contractual		price
						life (years)							life (years)
	Exercise price:
	$0.96			1,277,500			6.48		$	0.96		1,141,328		6.48	$	0.96
	$1.68			122,824			7.19			1.68		86,535		7.18		1.68
	$2.08			121,250			8.16			2.08		55,842		8.16		2.08
	$7.16 – $9.38			837,905			9.04			7.9		106,399		8.24		8.49
	$10.00-$10.63			292,407			8.88			10.21		87,682		8.31		10
				2,651,886								1,477,786
	The weighted-average grant date fair value of the stock options granted during the years ended December 31, 2013, 2012 and 2011 was $5.04 per share, $6.97 per share and $2.64 per share, respectively. The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:
			2013		2012	2011
	Risk-free interest rate		1.3% – 2.3%		1.2% – 2.25%		2.25	%
	Expected volatility		57% – 80%		80%		80	%
	Expected term (years)		7		7		7
	Expected dividend yield		0%		0%		0	%
	The Company used the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term of stock option grants to employees due to the Company’s limited operating history. The expected stock-price volatility assumption is based on the historical volatility of the Company’s stock, which is obtained from public data sources. The risk-free interest rate is based on the implied yield on U.S. Treasury zero coupon bonds for periods commensurate with the expected term of the options. The dividend yield on the Company’s common stock is estimated to be zero based on the fact that the Company has not paid and does not intend to pay dividends during the expected term of its stock options.
	Share-based compensation expense for stock options granted to employees and directors is based on the estimated grant date fair value of options recognized ratably over the requisite service period, which is the vesting period of the award. The level of forfeitures expected to occur was estimated based on the Company’s historical experience of pre-vesting cancellations for terminated employees. The Company believes that its estimates are based on outcomes that are reasonably likely to occur. To the extent actual forfeitures differ from its estimates, such amounts will be recorded as a cumulative adjustment in the period the estimates are revised.
	During the year ended December 31, 2013, 35,717 options were exercised resulting in $0.1 million of proceeds to the Company. During the year ended December 31, 2012, certain of those option awards exercised were early exercises resulting in the issuance of 23,017 shares of restricted stock. As of December 31, 2013, 14,670 shares of the restricted stock were vested, 2,778 were forfeited and the remainder will continue to vest over the requisite service period.
	Share-based compensation expense totaled $2.6 million, $1.4 million, and $0.8 million for the years ended December 31, 2013, 2012, and 2011, respectively, which is included in research and development and general and administrative expenses in the accompanying consolidated statements of operations. The total unrecognized share-based compensation cost at December 31, 2013 amounted to $5.1 million, net of estimated forfeitures, which is expected to be recognized over a weighted-average remaining vesting period of approximately 2.96 years.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	-11	Net Loss Per Share
	Net loss per share was determined in accordance with the two-class method. This method is used for computing basic net loss per share when companies have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of the company. Under the two-class method, net loss is allocated between common shares and other participating securities based on their participating rights in both distributed and undistributed earnings. The Company’s Series A Convertible Preferred Stock were participating securities, since the stockholders were entitled to share in dividends declared by the board of directors with the common stock based on their equivalent common shares. Basic net loss per share is computed by dividing net loss available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period. Because the holders of the participating preferred stock were not contractually required to share in the Company’s losses, in applying the two-class method to compute basic net loss per common share, no allocation to preferred stock was made for the years ended December 31, 2013, 2012, and 2011. Potential common shares in the diluted net loss per share computation are excluded as they would be anti-dilutive.
	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of December 31, 2013, 2012, and 2011, as they would be anti-dilutive.
			December 31,
			2013		2012		2011
	Convertible preferred stock			—		—		6,899,737
	Stock options, warrants and unvested restricted stock			2,725,454		2,153,900		1,510,000

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	-12	Income Taxes
	The Company did not record an income tax benefit on its loss before tax for the year ended December 31, 2013. Following the transfer of the worldwide rights to dalbavancin to the Company’s wholly-owned foreign subsidiary in 2012, losses incurred by the Company result in net operating losses outside the United States (U.S.) which have no anticipated future benefit; therefore, are not recorded as deferred tax assets. Also as a result of the transfer, the Company generated taxable income in the U.S. and recorded income tax expense of $1.3 million for the year ended December 31, 2013 which is comprised of $2.3 million current income tax expense and $1.0 million deferred income tax benefit. During the first quarter of 2013, the research and development tax credit was reinstated and as a result, the Company recorded a $1.0 million reduction in its income taxes payable and deferred charge for the expected 2012 credit.
	The U.S. and state income tax expense associated with the transfer of the worldwide rights to dalbavancin was deferred on the balance sheet in accordance with ASC 740-10-25-3(e).
	For the years ended December 31, 2013, 2012 and 2011, income from operations before taxes consisted of the following (in thousands):
			2013			2012			2011
	U.S. operations		$	2,167		$	(13,834	)	$	(35,544	)
	Foreign operations			(63,030	)		(48,705	)		—
			$	(60,863	)	$	(62,539	)	$	(35,544	)
	Income tax expense (benefit) attributable to income from operations was $1.3 million, $0 million and ($2.5) million for the years ended December 31, 2013, 2012 and 2011, respectively, and differed from the amounts computed by applying the applicable U.S. federal income tax rate to pretax income from operations as a result of the following:
			2013			2012			2011
	Federal statutory rate			34	%		35	%		34	%
	States taxes, net of federal benefit			0	%		0	%		4	%
	Foreign rate differential			(9	)%		(8	)%		—
	Permanent items—change in contingent consideration			(1	)%		(1	)%		(1	)%
	Research and development credits			0	%		1	%		—
	Advanced pricing agreement			(26	)%		—			—
	Valuation allowance			—			(27	)%		(30	)%
				(2	)%		—	%		7	%
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and their basis for income tax purposes and the tax effects of net operating losses and tax credit carry-forwards. The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2013 and 2012 are presented below (in thousands).
			2013			2012
	Deferred tax assets:
	Stock compensation		$	1,948		$	1,033
	Professional fees			35			—
	Foreign net operating losses			—			12,176
	Total deferred tax assets		$	1,983		$	13,209
	Deferred tax liabilities:
	Fixed assets		$	319		$	—
	Total deferred tax liabilities		$	319		$	—
	Valuation allowance		$	—		$	12,428
	Net deferred tax assets		$	1,664		$	781
	Valuation allowances reduce deferred tax assets to the amounts that are more-likely-than-not to be realized. During the year ended December 31, 2013, the Company determined that due to the advanced pricing with the Dutch Tax Administration that was finalized in March 2013 no net operating losses related to the foreign losses incurred since June 2012 exist that would allow the Company to offset future taxable income. Therefore, the Company removed the deferred tax asset related to the foreign net operating losses and the corresponding valuation allowance during the year ended December 31, 2013. This adjustment does not have a net impact on the balance sheet or income tax expense. During the year ended December 31, 2013, the Company has recorded deferred tax assets that were determined to be more-likely-than-not to be realized and therefore no valuation allowance was recorded as of December 31, 2013. The Company regularly evaluates the likelihood of the realization of its deferred tax assets and reduces the carrying amount of those deferred tax assets by a valuation allowance to the extent it believes a portion will not be realized. The Company considers many factors when assessing the likelihood of future realization of its deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income, the carryback availability and carryforward periods available to it for tax reporting purposes and other relevant factors. Significant judgment is required in making this assessment.
	Classification of net deferred tax assets on the consolidated balance sheets is as follows (in thousands):
			December 31,
			2013			2012
	Current assets		$	35		$	781
	Non-current assets			1,629			—
	Net deferred tax assets		$	1,664		$	781
	At December 31, 2013, the Company had no net operating loss carryforwards for federal income tax purposes due to the tax gain recognized in the United States from transfer of the worldwide rights to dalbavancin to a wholly-owned foreign subsidiary. Likewise, the Company has no net operating loss carryforwards for state income tax purposes.
	The total amount of federal, foreign, state and local unrecognized tax benefits was $1.4 million and $1.1 million at December 31, 2013 and 2012, respectively. A reconciliation of the Company’s changes in uncertain tax positions is as follows (in thousands):
	Balance at December 31, 2012		$	1,117
	Increase related to prior year tax positions			242
	Increase related to current year tax positions			18
	Balance at December 31, 2013		$	1,377
	Included in the balance of total unrecognized tax benefits at December 31, 2013, are potential benefits of $1.4 million that if recognized, would affect the effective rate on income from operations. Interest and penalties accrued during both 2013 and 2012 related to the unrecognized tax positions were immaterial.
	The Company files income tax returns in the United States, the Netherlands, the United Kingdom and various U.S. state jurisdictions. The Company’s U.S and state tax returns remain subject to examination for 2009 and subsequent periods.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	-13	Commitments and Contingencies
		(a)	Employment Agreements
	The Company has employment agreements with certain employees which require the funding of a specified level of payments if certain events, such as a change in control or termination without cause, occur.
		(b)	Consulting and Other Business Arrangements
	In the course of normal business operations, the Company has agreements with contract service providers to assist in the performance of its research and development and manufacturing activities. The Company can elect to discontinue the work under these agreements at any time. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and even long-term commitments of cash.
	The Company has entered into a supply agreement, as amended, with Gnosis Bioresearch srl., or Gnosis, to supply it with the drug substance for dalbavancin in the form of injectable grade powder. Gnosis has agreed to produce a specified percentage of the Company’s worldwide demand for drug substance. Under this agreement, Gnosis is required to manufacture and supply, and the Company is required to purchase specified minimum annual purchase volumes of drug substance at specified prices. The agreement expires on June 12, 2017, subject to automatic renewal for successive two-year periods. The Company currently has purchase commitments of approximately $29.1 million associated with the first three years of the initial five-year term of the agreement. The Company has agreed with Gnosis to define the purchase commitments for the subsequent two years of the initial term by a date specified in the agreement. The increase in the commitment of $6.5 million from December 31, 2012 is primarily due to an increase in the committed volumes in the amended agreement and the impact of the change in foreign exchange rates. As of December 31, 2013, the Company has incurred approximately $2.8 million under the purchase commitments in this contract. The contracted amounts are estimated to be paid from 2014 through 2016. In addition, the Company had purchase commitments of approximately $6.0 million to Gnosis for the production of validation batches. As of December 31, 2013, the Company has incurred the full commitment of $6.0 million related to these batches. The Company has also identified possible secondary suppliers of drug substance and is currently engaged in a technology transfer process. The Company has entered into agreements with potential secondary suppliers of drug substance to manufacture registration and validation batches. The Company has purchase commitments of up to approximately $7.2 million under these agreements. As of December 31, 2013, we have incurred $0.8 million under these agreements.
	The Company has entered into a development and supply agreement with Hospira Worldwide, Inc., or Hospira, for its fill and finish services. Under this agreement, Hospira is required to supply and the Company is required to purchase a specified percentage of its commercial requirements of dalbavancin. The Company is also required to pay Hospira aggregate development fees of approximately $1.7 million based on the occurrence of specified milestone events. Through December 31, 2013, the Company has incurred the full commitment related to the development fee, which has been included in research and development expense in the consolidated statement of operations. The agreement expires five years after the first commercial sale of dalbavancin, subject to an automatic renewal for an indefinite period.
		(c)	Leasing Arrangements
	During 2012, the Company entered into a lease for office space in Chicago, Illinois, which the Company uses for corporate and commercial functions. The Company has agreed to pay aggregate rental fees of approximately $1.2 million over the 65 month term. The Company has provided a security deposit in the form of a letter of credit for the benefit of the landlord in the amount of $0.5 million, which amount will be reduced incrementally over the term of the lease. Also during 2012, the Company entered into a lease for office space in Branford, Connecticut, which the Company uses for research and development, clinical and regulatory functions. The Company has agreed to pay aggregate rental fees of approximately $1.8 million over the 62 month term. The Company has provided a security deposit in the form of a letter of credit for the benefit of the landlord in the amount of $0.6 million, which increased by $0.3 million since December 31, 2012 because the landlord financed leasehold improvements in excess of the construction allowance during that period. The amount will be reduced incrementally over the term of the lease.
	The letters of credit outstanding are collateralized with certificates of deposit.
	The minimum aggregate future lease commitments required under these agreements are as follows:
	Years ending December 31,
	2014		$	576
	2015			601
	2016			608
	2017			624
	2018			127
	Total future minimum payments		$	2,536
		(d)	Contingencies
	From time to time, the Company may be involved in various legal actions arising out of the ordinary conduct of business. In the opinion of management, the ultimate disposition of such actions will not materially affect the Company’s consolidated financial position, results of operations or cash flows.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Accrued Expenses	'
	-14	Accrued Expenses
	Accrued expenses consist of the following:
			December 31,
			2013		2012
	Contract research organizations		$	1,360	$	8,309
	Contract manufacturers (a)			2,746		540
	Compensation and related benefits			2,279		1,428
	Professional fees			87		141
	Other expenses			644		184
			$	7,116	$	10,602
	(a)	As of December 31, 2013, accrued expenses-contract manufacturers included $1.8 million related to manufacturing supplies recorded in other assets (see note 7, Other Assets).

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Selected Quarterly Financial Data	'
	-15	Selected Quarterly Financial Data (unaudited)
	The following table contains quarterly financial information for the years ended December 31, 2013 and 2012 (in thousands, except share and per share data). The operating results for any quarter are not necessarily indicative of results for any future period.
			2013
			March 31			June 30			September 30			December 31
	Operating expenses:
	Research and development		$	11,092		$	13,179		$	5,928		$	7,118
	General and administrative			4,050			4,514			4,823			5,215
	Acquisition related charges, net			284			289			266			214
	Operating loss			15,426			17,982			11,017			12,547
	Other expense, net			93			643			625			2,530
	Loss before income taxes			15,519			18,625			11,642			15,077
	Income tax expense			248			210			257			563
	Net loss		$	(15,767	)	$	(18,835	)	$	(11,899	)	$	(15,640	)
	Net loss per common share—Basic and Diluted		$	(0.86	)	$	(0.75	)	$	(0.45	)	$	(0.59	)
	Weighted-average common shares—Basic and Diluted			18,367,540			25,169,543			26,620,497			26,623,724
			2012
			March 31			June 30			September 30			December 31
	Operating expenses:
	Research and development		$	6,771		$	16,528		$	18,956		$	9,440
	General and administrative			1,221			2,392			2,552			3,622
	Acquisition related charges, net			268			272			277			280
	Operating loss			8,260			19,192			21,786			13,342
	Other income, net			(2	)		(4	)		(12	)		(23	)
	Loss before income taxes			8,258			19,188			21,774			13,319
	Income tax expense			—			—			—			—
	Net loss		$	(8,258	)	$	(19,188	)	$	(21,774	)	$	(13,319	)
	Net loss per common share—Basic and Diluted		$	(132.12	)	$	(260.25	)	$	(1.47	)	$	(0.73	)
	Weighted-average common shares—Basic and Diluted			62,500			73,727			14,781,419			18,359,667

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	-16	Subsequent Events
	The Company has evaluated subsequent events occurring after the balance sheet date through the date the financial statements were issued. Based on the evaluation, the Company has determined there were no material events or transactions that require recognition or disclosure in the consolidated financial statements.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation and Principles of Consolidation	'
		(a)	Basis of Presentation and Principles of Consolidation
	The consolidated financial statements of the Company are prepared on the accrual basis of accounting. All intercompany accounts and transactions have been eliminated.
Use of Estimates	'
		(b)	Use of Estimates
	The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.
Development Stage Company	'
		(c)	Development Stage Company
	The Company’s primary activities since inception have been organizing and staffing the Company, business planning, raising capital and acquiring and developing dalbavancin. Accordingly, the Company is considered to be in the “development stage” and has prepared the accompanying consolidated financial statements in accordance with the provisions of the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) No. 915, Accounting for Development Stage Entities.
Cash and Cash Equivalents and Restricted Cash	'
		(d)	Cash and Cash Equivalents and Restricted Cash
	The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash resources principally in money market funds.
	Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted in the next twelve months, the restricted cash account is classified as current. Included within Restricted Cash on the Company’s December 31, 2013 and 2012 consolidated balance sheet are certificates of deposit for $1.1 million and $0.9 million, respectively, which are being held by a third party bank as collateral for the irrevocable letters of credit issued in connection with the Company’s two office leases (see note 13, Commitments and Contingencies).
Financial Instruments	'
		(e)	Financial Instruments
	The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is established that prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:
		Level 1:	Observable inputs such as quoted prices in active markets for identical assets or liabilities;
		Level 2:	Inputs other than the quoted prices included in Level 1 that are observable for the asset or liability either directly or indirectly; and
		Level 3:	Unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions.
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. See note 4, Financial Instruments, for additional information.
Short-term Investments	'
		(f)	Short-term Investments
	As of December 31, 2013 , cash equivalents and short-term investments consist of investments in money market accounts, federal agency bonds and corporate entity commercial paper and bonds that are classified as available-for-sale pursuant to ASC 320, Investments—Debt and Equity Securities. The Company classifies investments available to fund current operations as current assets on its balance sheet. Investments are classified as long-term assets on the balance sheet if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year. All of the Company’s investments are classified as current.
	The fair value of these securities is based on quoted prices for identical or similar assets. If a decline in the fair value is considered other-than-temporary the unrealized loss, if any, would be transferred from other comprehensive loss to the statement of operations. There were no charges taken for other-than-temporary declines in fair value of short-term investments during 2013. Realized gains and losses are determined using the specific identification method and are included in interest income in the statement of operations. Realized gains and losses recognized during the years ended December 31, 2013 and 2012 were immaterial.
	The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers its intent to sell, or whether it is more likely than not that the Company will be required to sell, the investment before recovery of the investment’s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and the duration of the impairment and changes in value subsequent to year end. As of December 31, 2013, there were no investments with a fair value that was lower than the amortized cost basis or any investments that had been in an unrealized loss position for a significant period. See note 4, Financial Instruments, for further information.
Deferred Financing Costs	'
		(g)	Deferred Financing Costs
	The Company capitalizes certain legal, accounting and other fees that are directly associated with in-process debt and equity financings as current assets until such financings occur. In the case of an equity financing, after occurrence, these costs are recorded in equity, net of proceeds received. In the case of a debt financing, these costs are recorded as other assets and amortized to interest expense over the term of the debt.
	As of December 31, 2013, the Company recorded debt financing costs of $0.4 million in connection with the debt financing completed in October 2013. The debt financing costs recorded in connection with the debt financing completed in March 2013 were expensed at the time the debt was repaid (see Note 9, Long-term Debt, for more information). The Company also incurred offering costs of $0.4 million in connection with the public offering of its common stock that closed in April 2013. The debt financing costs are recorded in other assets on the consolidated balance sheet, net of accumulated amortization. The offering costs are recorded in equity as an offset to the proceeds received from the sale of the shares.
Other Intangible Assets	'
		(h)	Other Intangible Assets
	The Company had an acquired in-process research and development (IPR&D) intangible asset of $15.3 million as of December 31, 2013 and 2012. Acquired IPR&D intangible assets represent the right to develop, use, sell or offer for sale intellectual property that the Company has acquired with respect to processes that have not been completed. These assets are required to be classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until their processes are completed and the Company receives regulatory approval from a major market to allow for the commencement of commercial marketing activities. At that time, the Company will determine the useful life of the asset, reclassify the asset out of in-process research and development and begin amortization. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.
	If the associated research and development effort is abandoned, the related assets likely will be written-off and the Company will record a non-cash impairment loss on its consolidated statement of operations. Acquired in-process research and development assets which are determined to have had a decrease in fair value are adjusted to fair value with an impairment charge. Such assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment. Intangible assets with definite useful lives will be amortized to their estimated residual values over their estimated useful lives and reviewed for impairment if certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See note 8, Goodwill and Intangibles, for additional information.
Goodwill	'
		(i)	Goodwill
	Goodwill represents the excess of purchase price over fair value of net assets acquired in a business combination accounted for by the acquisition method of accounting and is not amortized, but subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment. The Company had goodwill of $5.8 million as of December 31, 2013 and 2012. See note 8, Goodwill and Intangibles, for additional information.
Property and Equipment	'
		(j)	Property and Equipment
	Property and equipment are recorded at cost, net of depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. The following table shows the estimated useful lives of the Company’s property and equipment:
	Classification		Estimated Useful Lives
	Leasehold improvements		Lesser of useful life or lease term
	Furniture and fixtures		5 years
	Information technology related		3-5 years
	Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized. Repairs and maintenance costs are expensed as incurred. See note 5, Property and Equipment, for additional information.
Impairment of Long-Lived Assets	'
		(k)	Impairment of Long-Lived Assets
	Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Operating Leases	'
		(l)	Operating Leases
	Rent expense related to leases is recorded on a straight-line basis over the term of the lease, including any rent free periods. The difference between actual rent payments and straight-line rent expense is recorded as deferred rent and included in other liabilities in the accompanying consolidated balance sheet.
Research and Development Costs	'
		(m)	Research and Development Costs
	Research and development costs are expensed as incurred and are primarily comprised of the following types of costs incurred in performing research and development activities:
		•		employee-related expenses, including salaries, benefits, travel and share-based compensation expense;
		•		external research and development expenses incurred under arrangements with third parties, such as contract research organizations (CROs), manufacturing organizations and consultants, including our scientific advisory board; and
		•		facilities and laboratory and other supplies.
Income Taxes	'
		(n)	Income Taxes
	The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which the temporary differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained. See note 12, Income Taxes, for additional information.
Share-Based Compensation	'
		(o)	Share-Based Compensation
	The Company uses share-based compensation in the form of stock options and restricted stock. Compensation expense is recognized in the consolidated statement of operations based on the estimated fair value of the shares at grant date. Compensation cost to be recognized reflects an estimate of the number of shares expected to vest after taking into consideration an estimate of forfeiture. The fair values of stock option grants are estimated as of the date of grant using the Black-Scholes option valuation model. The fair value of option grants are based on the fair value of the Company’s common stock on the date of grant. See note 10, Stockholders’ Equity and Stock Compensation, for additional information.
Warrant Accounting	'
		(p)	Warrant Accounting
	In connection with the loan agreement with Oxford Finance LLC, or Oxford, discussed in note 9, Long-term Debt, the Company granted warrants for the purchase of the Company’s common stock. The Company accounted for these common stock warrants in accordance with applicable accounting guidance provided in ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, as equity instruments based on the specific terms of the warrant agreements.
Concentrations	'
		(q)	Concentrations
	The Company maintains cash and cash equivalent balances with financial institutions which, at times, may exceed insurance limits established by the Federal Deposit Insurance Corporation. Management does not consider this to be a significant risk due to the long-standing reputation of these financial institutions.
	The Company has entered into agreements with a contract manufacturer to manufacture clinical and future commercial supplies of dalbavancin. The Company has also entered into an agreement with a contract manufacturer to supply the drug substance for dalbavancin in the form of injectable grade powder. The loss of either of these suppliers could have a material adverse effect upon the Company’s operations.

Property_and_Equipment_Net_Tab

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2013
Estimated Useful Lives of Property and Equipment	'
	Property and equipment and related accumulated depreciation are as follows (in thousands):
		December 31,			December 31,
		2013			2012
	Furniture and fixtures	$	673		$	641
	Information technology related		348			226
	Leasehold improvements		143			129
			1,164			996
	Less: accumulated depreciation		(267	)		(15	)
	Property and equipment, net	$	897		$	981
Depreciation [Member]	'
Estimated Useful Lives of Property and Equipment	'
	The following table shows the estimated useful lives of the Company’s property and equipment:
	Classification	Estimated Useful Lives
	Leasehold improvements	Lesser of useful life or lease term
	Furniture and fixtures	5 years
	Information technology related	3-5 years

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Summary of Prepaid Expenses and Other Current Assets	'
	Prepaid expenses and other current assets consist of the following (in thousands):
			December 31,		December 31,
			2013		2012
	Income tax receivable		$	1,971	$	—
	Deferred tax asset			35		781
	Prepaid manufacturing fees (a)			665		4,550
	Prepaid insurance			262		353
	Other prepaid assets			381		98
	Other receivables			53		62
			$	3,367	$	5,844
	(a)	During 2012, the Company paid amounts to its primary manufacturer of active pharmaceutical ingredient for the production of validation batches that were produced in 2013.

Financial_Instruments_Tables

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2013
Investments All Other Investments [Abstract]	'
Financial Assets and Liabilities Measured at Fair Value and Fair Value Hierarchy of Valuation Inputs Used to Determine Fair Value	'
	The following table presents information about the Company’s financial assets that have been measured at fair value at December 31, 2013 and 2012, and indicates the fair value hierarchy of the valuation inputs used to determine such fair value (in thousands):
		2013
		Fair Value		Level 1		Level 2		Level 3
	Assets:
	Money market fund investments	$	27,156	$	27,156	$	—	$	—
	Available for sale securities:
	Federal agency bonds		14,847		14,847		—		—
	Corporate commercial paper		3,998		3,998		—		—
	Corporate bonds		4,035		4,035		—		—
	Total available for sale securities	$	22,880	$	22,880	$	—	$	—
	Liabilities:
	Contingent Liability	$	20,889	$	—	$	—	$	20,889
		2012
		Fair Value		Level 1		Level 2		Level 3
	Assets:
	Money market fund investments	$	30,537	$	30,537	$	—	$	—
	Available for sale securities:
	Federal agency bonds		8,090		8,090		—		—
	Corporate commercial paper		3,997		3,997		—		—
	Corporate bonds		1,007		1,007		—		—
	Total available for sale securities	$	13,094	$	13,094	$	—	$	—
	Liabilities:
	Contingent Liability	$	19,836	$	—	$	—	$	19,836
Fair Value Measurements Using Significant Unobservable Inputs	'
	Additional information for the Company’s recurring fair value measurements using significant unobservable inputs (Level 3 inputs) was follows (in thousands):
	Balance at December 31, 2011	$	18,739
	Contingent consideration expense		1,097
	Transfers in and/or out of Level 3		—
	Balance at December 31, 2012	$	19,836
	Contingent consideration expense		1,053
	Transfers in and/or out of Level 3		—
	Balance at December 31, 2013	$	20,889

Other_Assets_Tables

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Components of Other Noncurrent Assets	'
	Other noncurrent assets consist of the following (in thousands):
		December 31,
		2013		2012
	Debt financing costs, net	$	419	$	—
	Deferred tax assets, net		1,629		—
	Manufacturing supplies		1,768		—
	Total other assets	$	3,816	$	—

Longterm_Debt_Tables

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Future Payments of Principal	'
	At December 31, 2013, future payments of principal are due as follows (in thousands):
	Years ending December 31,
	2014	$	—
	2015		1,250
	2016		5,000
	2017		8,750
	2018		10,000
	Total long-term debt	$	25,000

Stockholders_Equity_and_Stock_1

Stockholders' Equity and Stock Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock Options Activity	'
	Activity with respect to options was as follows:
		Options Outstanding								Exercisable Options
		Shares			Weighted			Weighted		Shares		Weighted
					average			average				average
					exercise			remaining				exercise
					price per			contractual				price per
					share			life (years)				share
	December 31, 2010		1,350,000		$	0.96			9.38		101,561	$	0.96
	Granted		160,000			1.68			—
	Forfeited or expired		—			—			—
	Exercised		—			—			—
	December 31, 2011		1,510,000		$	1.06			8.52		527,181	$	0.97
	Granted		730,309			7.73			—
	Forfeited or expired		63,188			4.94			—
	Exercised		38,642			3.78			—
	December 31, 2012		2,138,479		$	3.17			8.21		952,499	$	1.4
	Granted		649,238			7.98			—
	Forfeited or expired		100,114			6.06			—
	Exercised		35,717			1.69			—
	December 31, 2013		2,651,886		$	4.26			7.67		1,477,786	$	2.12
Summary of Options Outstanding and Exercisable	'
	The following table summarizes additional information regarding options outstanding and exercisable at December 31, 2013:
		Options Outstanding								Exercisable Options
		Number of			Weighted			Weighted		Number of		Weighted		Weighted
		options			average			average		options		average		average
		outstanding			remaining			exercise		exercisable		remaining		exercise
		at year end			contractual			price		at year end		contractual		price
					life (years)							life (years)
	Exercise price:
	$0.96		1,277,500			6.48		$	0.96		1,141,328		6.48	$	0.96
	$1.68		122,824			7.19			1.68		86,535		7.18		1.68
	$2.08		121,250			8.16			2.08		55,842		8.16		2.08
	$7.16 – $9.38		837,905			9.04			7.9		106,399		8.24		8.49
	$10.00-$10.63		292,407			8.88			10.21		87,682		8.31		10
			2,651,886								1,477,786
Assumptions for Estimating Fair Value of Options Granted Using Black-Scholes Option Pricing Model	'
	The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:
		2013		2012	2011
	Risk-free interest rate	1.3% – 2.3%		1.2% – 2.25%		2.25	%
	Expected volatility	57% – 80%		80%		80	%
	Expected term (years)	7		7		7
	Expected dividend yield	0%		0%		0	%

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding	'
	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of December 31, 2013, 2012, and 2011, as they would be anti-dilutive.
		December 31,
		2013		2012		2011
	Convertible preferred stock		—		—		6,899,737
	Stock options, warrants and unvested restricted stock		2,725,454		2,153,900		1,510,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Summary of Income Before Income Taxes	'
	For the years ended December 31, 2013, 2012 and 2011, income from operations before taxes consisted of the following (in thousands):
		2013			2012			2011
	U.S. operations	$	2,167		$	(13,834	)	$	(35,544	)
	Foreign operations		(63,030	)		(48,705	)		—
		$	(60,863	)	$	(62,539	)	$	(35,544	)
Reconciliation Between Effective Tax Rate and Federal Statutory Rate	'
	Income tax expense (benefit) attributable to income from operations was $1.3 million, $0 million and $2.5 million for the years ended December 31, 2013, 2012 and 2011, respectively, and differed from the amounts computed by applying the applicable U.S. federal income tax rate to pretax income from operations as a result of the following:
		2013			2012			2011
	Federal statutory rate		34	%		35	%		34	%
	States taxes, net of federal benefit		0	%		0	%		4	%
	Foreign rate differential		(9	)%		(8	)%		—
	Permanent items—change in contingent consideration		(1	)%		(1	)%		(1	)%
	Research and development credits		0	%		1	%		—
	Advanced pricing agreement		(26	)%		—			—
	Valuation allowance		—			(27	)%		(30	)%
			(2	)%		—	%		7	%
Components of Deferred Tax Assets and Liabilities	'
	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2013 and 2012 are presented below (in thousands).
		2013			2012
	Deferred tax assets:
	Stock compensation	$	1,948		$	1,033
	Professional fees		35			—
	Foreign net operating losses		—			12,176
	Total deferred tax assets	$	1,983		$	13,209
	Deferred tax liabilities:
	Fixed assets	$	319		$	—
	Total deferred tax liabilities	$	319		$	—
	Valuation allowance	$	—		$	12,428
	Net deferred tax assets	$	1,664		$	781
Classification of Net Deferred Tax Assets	'
	Classification of net deferred tax assets on the consolidated balance sheets is as follows (in thousands):
		December 31,
		2013			2012
	Current assets	$	35		$	781
	Non-current assets		1,629			—
	Net deferred tax assets	$	1,664		$	781
Schedule of Unrecognized Tax Benefits	'
	A reconciliation of the Company’s changes in uncertain tax positions is as follows (in thousands):
	Balance at December 31, 2012	$	1,117
	Increase related to prior year tax positions		242
	Increase related to current year tax positions		18
	Balance at December 31, 2013	$	1,377

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Minimum Aggregate Future Lease Commitments	'
	The minimum aggregate future lease commitments required under these agreements are as follows:
	Years ending December 31,
	2014	$	576
	2015		601
	2016		608
	2017		624
	2018		127
	Total future minimum payments	$	2,536

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Summary of Accrued Expenses	'
	Accrued expenses consist of the following:
			December 31,
			2013		2012
	Contract research organizations		$	1,360	$	8,309
	Contract manufacturers (a)			2,746		540
	Compensation and related benefits			2,279		1,428
	Professional fees			87		141
	Other expenses			644		184
			$	7,116	$	10,602
	(a)	As of December 31, 2013, accrued expenses-contract manufacturers included $1.8 million related to manufacturing supplies recorded in other assets (see note 7, Other Assets).

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary of Selected Quarterly Financial Data	'
	The following table contains quarterly financial information for the years ended December 31, 2013 and 2012 (in thousands, except share and per share data). The operating results for any quarter are not necessarily indicative of results for any future period.
		2013
		March 31			June 30			September 30			December 31
	Operating expenses:
	Research and development	$	11,092		$	13,179		$	5,928		$	7,118
	General and administrative		4,050			4,514			4,823			5,215
	Acquisition related charges, net		284			289			266			214
	Operating loss		15,426			17,982			11,017			12,547
	Other expense, net		93			643			625			2,530
	Loss before income taxes		15,519			18,625			11,642			15,077
	Income tax expense		248			210			257			563
	Net loss	$	(15,767	)	$	(18,835	)	$	(11,899	)	$	(15,640	)
	Net loss per common share—Basic and Diluted	$	(0.86	)	$	(0.75	)	$	(0.45	)	$	(0.59	)
	Weighted-average common shares—Basic and Diluted		18,367,540			25,169,543			26,620,497			26,623,724
		2012
		March 31			June 30			September 30			December 31
	Operating expenses:
	Research and development	$	6,771		$	16,528		$	18,956		$	9,440
	General and administrative		1,221			2,392			2,552			3,622
	Acquisition related charges, net		268			272			277			280
	Operating loss		8,260			19,192			21,786			13,342
	Other income, net		(2	)		(4	)		(12	)		(23	)
	Loss before income taxes		8,258			19,188			21,774			13,319
	Income tax expense		—			—			—			—
	Net loss	$	(8,258	)	$	(19,188	)	$	(21,774	)	$	(13,319	)
	Net loss per common share—Basic and Diluted	$	(132.12	)	$	(260.25	)	$	(1.47	)	$	(0.73	)
	Weighted-average common shares—Basic and Diluted		62,500			73,727			14,781,419			18,359,667

Nature_of_Business_Organizatio1

Nature of Business, Organization and Liquidity - Additional Information (Detail) (USD $)

2 Months Ended

3 Months Ended

12 Months Ended

50 Months Ended

Dec. 31, 2009

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Organization Consolidation And Presentation Of Financial Statements [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

Net loss

-714,000

-15,640,000

-11,899,000

-18,835,000

-15,767,000

-13,319,000

-21,774,000

-19,188,000

-8,258,000

-62,141,000

-62,539,000

-33,033,000

-11,014,000

-169,441,000

Accumulated deficit during the development stage

'

-169,441,000

'

'

'

-107,300,000

'

'

'

-169,441,000

-107,300,000

'

'

-169,441,000

Additional borrowing capacity available

'

$15,000,000

'

'

'

'

'

'

'

$15,000,000

'

'

'

$15,000,000

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
	Lease
Summary Of Significant Accounting Policies [Line Items]	'	'
Certificates of deposit	$1,100,000	$900,000
Number of office leases	2	'
Realized gains or losses on available for sale securities	0	0
Goodwill	5,811,000	5,811,000
Debt Financing [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Deferred financing costs	400,000	'
Equity Financing [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Deferred financing costs	400,000	'
In-Process Research and Development [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Acquired in-process research and development intangible assets	$15,300,000	$15,300,000
Minimum [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Contractual maturity date of investments	'1 year	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2013
Leasehold Improvements [Member]	'
Summary Of Significant Accounting Policies [Line Items]	'
Estimated Useful Lives, Leasehold improvements	'Lesser of useful life or lease term
Furniture and Fixtures [Member]	'
Summary Of Significant Accounting Policies [Line Items]	'
Estimated Useful Lives	'5 years
Minimum [Member] | Information Technology Related [Member]	'
Summary Of Significant Accounting Policies [Line Items]	'
Estimated Useful Lives	'3 years
Maximum [Member] | Information Technology Related [Member]	'
Summary Of Significant Accounting Policies [Line Items]	'
Estimated Useful Lives	'5 years

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'
Income tax receivable	$1,971	'
Deferred tax assets	35	781
Prepaid manufacturing fees	665	4,550	[1]
Prepaid insurance	262	353
Other prepaid assets	381	98
Other receivables	53	62
Prepaid expenses and other current assets , Total	$3,367	$5,844
[1]	During 2012, the Company paid amounts to its primary manufacturer of active pharmaceutical ingredient for the production of validation batches that were produced in 2013.

Financial_Instruments_Financia

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value and Fair Value Hierarchy of Valuation Inputs Used to Determine Fair Value (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Assets:	'	'
Assets, Fair Value	$22,880	$13,094
Contingent Liability [Member]	'	'
Liabilities:	'	'
Contingent Liability	20,889	19,836
Money Market Fund Investments [Member]	'	'
Assets:	'	'
Assets, Fair Value	27,156	30,537
Federal Agency Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	14,847	8,090
Corporate Commercial Paper [Member]	'	'
Assets:	'	'
Assets, Fair Value	3,998	3,997
Corporate Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	4,035	1,007
Level 1 [Member]	'	'
Assets:	'	'
Assets, Fair Value	22,880	13,094
Level 1 [Member] | Contingent Liability [Member]	'	'
Liabilities:	'	'
Contingent Liability	'	'
Level 1 [Member] | Money Market Fund Investments [Member]	'	'
Assets:	'	'
Assets, Fair Value	27,156	30,537
Level 1 [Member] | Federal Agency Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	14,847	8,090
Level 1 [Member] | Corporate Commercial Paper [Member]	'	'
Assets:	'	'
Assets, Fair Value	3,998	3,997
Level 1 [Member] | Corporate Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	4,035	1,007
Level 2 [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 2 [Member] | Contingent Liability [Member]	'	'
Liabilities:	'	'
Contingent Liability	'	'
Level 2 [Member] | Money Market Fund Investments [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 2 [Member] | Federal Agency Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 2 [Member] | Corporate Commercial Paper [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 2 [Member] | Corporate Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 3 [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 3 [Member] | Contingent Liability [Member]	'	'
Liabilities:	'	'
Contingent Liability	20,889	19,836
Level 3 [Member] | Money Market Fund Investments [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 3 [Member] | Federal Agency Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 3 [Member] | Corporate Commercial Paper [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 3 [Member] | Corporate Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'

Financial_Instruments_Fair_Val

Financial Instruments - Fair Value Measurements Using Significant Unobservable Inputs (Detail) (Level 3 [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Level 3 [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning Balance	$19,836	$18,739
Contingent consideration expense	1,053	1,097
Transfers in and/or out of Level 3	'	'
Ending Balance	$20,889	$19,836

Financial_Instruments_Addition

Financial Instruments - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Financial Instruments [Line Items]	'	'	'
Assumed payment probability of contingent consideration liability	85.00%	80.00%	'
Level 3 [Member]	'	'	'
Financial Instruments [Line Items]	'	'	'
Fair value of contingent consideration liability	$20,889	$19,836	$18,739

Property_and_Equipment_Propert

Property and Equipment - Property and Equipment and Related Accumulated Depreciation (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property Plant And Equipment Useful Life And Values [Abstract]	'	'
Furniture and fixtures	$673	$641
Information technology related	348	226
Leasehold improvements	143	129
Property and equipment, gross	1,164	996
Less: accumulated depreciation	-267	-15
Property and equipment, net	$897	$981

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property Plant And Equipment Useful Life And Values [Abstract]	'	'
Depreciation expense	$300,000	$15,000

Acquisitions_Milestone_Payment1

Acquisitions - Milestone Payment - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended	12 Months Ended
	Oct. 31, 2013	Mar. 31, 2011	Dec. 31, 2009	Dec. 31, 2009	Dec. 31, 2013	Dec. 31, 2012	Dec. 11, 2009
Business Combinations [Abstract]	'	'	'	'	'	'	'
Total upfront consideration	'	'	$10,000,000	'	'	'	'
Contingent Potential Refund of Initial Purchase Price Related To Acquisition	'	'	6,000,000	6,000,000	'	'	'
Liability Recognized on Completion of Assessment successful clinical development, regulatory approval and commercial sale of dalbavancin	'	'	'	'	20,889,000	19,836,000	5,800,000
Contingent Assets Reassessed For Recovery	'	'	'	'	'	'	6,000,000
Fair value of contingent asset	'	'	'	'	'	'	600,000
Proceeds from contingent receivable	'	6,000,000	'	'	'	'	'
Additional milestone payment	'	'	$25,000,000	$25,000,000	'	'	'
Period of milestone payment	'	'	'	'5 years	'	'	'
Accrued interest rate on outstanding principal amount of promissory note	14.00%	'	'	10.00%	'	'	'

Other_Assets_Schedule_of_Other

Other Assets - Schedule of Other Noncurrent Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'
Debt financing costs, net	$419	'
Deferred tax assets, net	1,629	'
Manufacturing supplies	1,768	'
Total other assets	$3,816	'

Goodwill_and_Intangibles_Addit

Goodwill and Intangibles - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'
Impairment on goodwill	$0	$0	$0
Impairment of In-Process Research and Development intangible assets	$0	$0	$0

Longterm_Debt_Additional_Infor

Long-term Debt - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended		50 Months Ended
	Oct. 31, 2013	Dec. 31, 2013	Dec. 31, 2009	Dec. 31, 2013	Mar. 31, 2013
Debt Disclosure [Abstract]	'	'	'	'	'
Aggregate principal amount	$25,000,000	'	'	'	$20,000,000
Common stock warrants available for grant	'	67,999	'	67,999	'
Common stock warrant exercise price	'	8.68	'	8.68	'
Fair value of warrants	'	$6.42	'	$6.42	'
Common stock warrants exercisable term	'	'7 years	'	'	'
Additional borrowing capacity available	15,000,000	'	'	'	'
Optional additional borrowing capacity available	30,000,000	'	'	'	'
Interest rate on first tranche till second tranche milestone	14.00%	'	10.00%	'	'
Interest rate on entire loan after second tranche milestone	12.75%	'	'	'	'
Debt instrument quarterly interest only payments end date	31-Dec-14	'	'	'	'
Debt instrument quarterly principal and interest payments start date	31-Mar-15	'	'	'	'
Debt instrument quarterly principal and interest payments end date	30-Sep-18	'	'	'	'
Debt instrument maturity date	31-Oct-18	'	'	'	'
Debt liquidity	2,000,000	'	'	'	'
Estimated long-term liability	'	$2,228,000	'	$2,228,000	'

Longterm_Debt_Future_Payments_

Long-term Debt - Future Payments of Principal (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'
2014	'
2015	1,250
2016	5,000
2017	8,750
2018	10,000
Total long-term debt	$25,000

Stockholders_Equity_and_Stock_2

Stockholders' Equity and Stock Compensation - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

50 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Apr. 17, 2013

Jul. 31, 2012

Dec. 31, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jul. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Apr. 17, 2013

Jul. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Apr. 30, 2012

Apr. 30, 2012

Incentive_Plan

Class A Preferred Stock [Member]

Class A Preferred Stock [Member]

Class A Preferred Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Underwriters Exercise of Over-allotment Option [Member]

Underwriters Exercise of Over-allotment Option [Member]

2012 Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Vested [Member]

Unvested [Member]

Minimum [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock sold under IPO and Secondary offering

8,222,500

8,625,000

'

'

'

'

'

'

'

'

'

'

1,072,500

1,125,000

'

'

'

'

'

'

Initial public offering and Secondary offering price per share

$7

$9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from public offering

$54,100,000

'

'

$54,104,000

$73,912,000

'

$128,016,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from initial public offering

'

73,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding Preferred Stock converted into common stock

'

9,649,738

'

'

'

'

'

'

-71,197,936

[1]

'

'

'

'

'

'

'

'

'

'

'

Number of restricted common shares issued

'

'

62,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of restricted stock

'

'

'

'

'

'

'

'

'

'

14,670

5,569

'

'

'

'

'

'

'

'

Convertible preferred stock issued

'

'

'

'

'

'

'

77,197,936

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of convertible preferred stock

'

'

'

'

22,000,000

36,000,000

77,198,000

77,197,936

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split

'

'

'

'

'

'

'

'

'

'one-for-8.000

'

'

'

'

'

'

'

'

'

'

Number of stock incentive plans

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock reserved for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

107,783

'

'

'

1,875,000

2,125,000

Number of shares of common stock outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

437,500

'

'

'

'

'

Percentage of number of shares of common stock outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.75%

'

'

'

'

'

Stock option outstanding granted, contractual term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

Stock option outstanding granted, vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

Weighted-average grant date fair value of the stock options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.04

$6.97

$2.64

'

'

Common stock dividend yield

'

'

'

0.00%

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of options exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,717

38,642

'

'

'

Proceeds from stock options exercised

'

'

'

55,000

146,000

'

201,000

'

'

'

'

'

'

'

'

100,000

'

'

'

'

Additional options exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

23,017

'

'

'

'

Restricted shares issued, forfeitures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,778

'

'

'

'

Share-based compensation expense for stock options

'

'

'

2,595,000

1,406,000

780,000

5,124,000

'

'

'

'

'

'

'

'

2,600,000

1,400,000

800,000

'

'

Unrecognized share-based compensation cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,100,000

'

'

'

'

Expected period of compensation cost to be recognized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 11 months 16 days

'

'

'

'

[1]

Does not include the $6,000,000 portion of the preferred stock that was redeemable upon certain conditions by the holders. These shares along with the non-redeemable portion of the Series A convertible preferred stock were converted to common stock at the time of the initial public offering (see note 10, Stockholders' Equity and Stock Compensation).

Stockholders_Equity_and_Stock_3

Stockholders' Equity and Stock Compensation - Stock Options Activity (Detail) (Stock Incentive Plan [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Stock Incentive Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Outstanding beginning balance, Shares, Exercisable Options	952,499	527,181	'	101,561
Outstanding ending balance, Shares, Exercisable Options	1,477,786	952,499	527,181	'
Outstanding beginning balance, Weighted average exercise price per share, Options Outstanding	$3.17	$1.06	$0.96	'
Outstanding balance, Weighted average remaining contractual life (Years), Options Outstanding	'7 years 8 months 1 day	'8 years 2 months 16 days	'8 years 6 months 7 days	'9 years 4 months 17 days
Granted, Weighted average exercise price per share, Options Outstanding	$7.98	$7.73	$1.68	'
Forfeited or expired, Weighted average exercise price per share, Options Outstanding	$6.06	$4.94	'	'
Exercised, Weighted average exercise price per share, Options Outstanding	$1.69	$3.78	'	'
Outstanding ending balance, Weighted average exercise price per share, Options Outstanding	$4.26	$3.17	$1.06	$0.96
Outstanding beginning balance, Shares, Options Outstanding	2,138,479	1,510,000	1,350,000	'
Granted, Shares, Options Outstanding	649,238	730,309	160,000	'
Forfeited or expired, Shares, Options Outstanding	100,114	63,188	'	'
Exercised, Shares, Options Outstanding	35,717	38,642	'	'
Outstanding ending balance, Shares, Options Outstanding	2,651,886	2,138,479	1,510,000	1,350,000
Outstanding beginning balance, Weighted average exercise price per share, Exercisable Options	$1.40	$0.97	'	$0.96
Outstanding ending balance, Weighted average exercise price per share, Exercisable Options	$2.12	$1.40	$0.97	'

Stockholders_Equity_and_Stock_4

Stockholders' Equity and Stock Compensation - Summary of Options Outstanding and Exercisable (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 24, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding, Number of options outstanding at year end	2,651,886	'
Exercisable Options, Number of options exercisable at year end	1,477,786	'
Exercise Price One [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$0.96	'
Options Outstanding, Number of options outstanding at year end	1,277,500	'
Exercisable Options, Number of options exercisable at year end	1,141,328	'
Options Outstanding, Weighted average remaining contractual life (Years)	'6 years 5 months 23 days	'
Exercisable Options, Weighted average remaining contractual life (Years)	'6 years 5 months 23 days	'
Options Outstanding, Weighted average exercise price	'	$0.96
Exercisable Options, Weighted average exercise price	'	$0.96
Exercise Price Two [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$1.68	'
Options Outstanding, Number of options outstanding at year end	122,824	'
Exercisable Options, Number of options exercisable at year end	86,535	'
Options Outstanding, Weighted average remaining contractual life (Years)	'7 years 2 months 9 days	'
Exercisable Options, Weighted average remaining contractual life (Years)	'7 years 2 months 5 days	'
Options Outstanding, Weighted average exercise price	'	$1.68
Exercisable Options, Weighted average exercise price	'	$1.68
Exercise Price Three [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$2.08	'
Options Outstanding, Number of options outstanding at year end	121,250	'
Exercisable Options, Number of options exercisable at year end	55,842	'
Options Outstanding, Weighted average remaining contractual life (Years)	'8 years 1 month 28 days	'
Exercisable Options, Weighted average remaining contractual life (Years)	'8 years 1 month 28 days	'
Options Outstanding, Weighted average exercise price	'	$2.08
Exercisable Options, Weighted average exercise price	'	$2.08
Exercise Price Four [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$7.16	'
Exercise price	$9.38	'
Options Outstanding, Number of options outstanding at year end	837,905	'
Exercisable Options, Number of options exercisable at year end	106,399	'
Options Outstanding, Weighted average remaining contractual life (Years)	'9 years 15 days	'
Exercisable Options, Weighted average remaining contractual life (Years)	'8 years 2 months 27 days	'
Options Outstanding, Weighted average exercise price	'	$7.90
Exercisable Options, Weighted average exercise price	'	$8.49
Exercise Price Five [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$10	'
Exercise price	$10.63	'
Options Outstanding, Number of options outstanding at year end	292,407	'
Exercisable Options, Number of options exercisable at year end	87,682	'
Options Outstanding, Weighted average remaining contractual life (Years)	'8 years 10 months 17 days	'
Exercisable Options, Weighted average remaining contractual life (Years)	'8 years 3 months 22 days	'
Options Outstanding, Weighted average exercise price	'	$10.21
Exercisable Options, Weighted average exercise price	'	$10

Stockholders_Equity_and_Stock_5

Stockholders' Equity and Stock Compensation - Assumptions for Estimating Fair Value of Options Granted Using Black-Scholes Option Pricing Model (Detail) (Stock Incentive Plan [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Estimated Fair Value Of Financial Instruments [Line Items]	'	'	'
Risk-free interest rate	'	'	2.25%
Expected volatility	'	80.00%	80.00%
Expected term (years)	'7 years	'7 years	'7 years
Expected dividend yield	0.00%	0.00%	0.00%
Minimum [Member]	'	'	'
Estimated Fair Value Of Financial Instruments [Line Items]	'	'	'
Risk-free interest rate	1.30%	1.20%	'
Expected volatility	57.00%	'	'
Maximum [Member]	'	'	'
Estimated Fair Value Of Financial Instruments [Line Items]	'	'	'
Risk-free interest rate	2.30%	2.25%	'
Expected volatility	80.00%	'	'

Net_Loss_Per_Share_Dilutive_Se

Net Loss Per Share - Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Class A Preferred Stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive shares excluded from the computations of diluted weighted average shares outstanding	'	'	6,899,737
Stock Options, Warrants and Unvested Restricted Stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive shares excluded from the computations of diluted weighted average shares outstanding	2,725,454	2,153,900	1,510,000

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

50 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Income Taxes Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Income tax benefit

'

'

'

'

'

'

'

'

$0

'

'

'

Income tax expense

563,000

257,000

210,000

248,000

'

'

'

'

1,278,000

0

-2,511,000

-4,533,000

Reduction in income taxes payable and deferred charge

'

'

'

1,000,000

'

'

'

'

'

'

'

'

Income tax expense (benefit)

'

'

'

'

'

'

'

'

2,300,000

'

'

'

Deferred income tax benefit

'

'

'

'

'

'

'

'

-1,013,000

'

-2,511,000

-6,824,000

Valuation allowance

0

'

'

'

12,428,000

'

'

'

0

12,428,000

'

0

Total amount of federal, foreign, state and local unrecognized tax benefits

1,377,000

'

'

'

1,117,000

'

'

'

1,377,000

1,117,000

'

1,377,000

Foreign Tax Authority [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Income Taxes Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Net operating loss carryforwards

0

'

'

'

'

'

'

'

0

'

'

0

Federal Jurisdiction [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Income Taxes Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Net operating loss carryforwards

0

'

'

'

'

'

'

'

0

'

'

0

State and Local Jurisdiction [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Income Taxes Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Net operating loss carryforwards

$0

'

'

'

'

'

'

'

$0

'

'

$0

Income_Taxes_Summary_of_Income

Income Taxes - Summary of Income Before Income Taxes (Detail) (USD $)

3 Months Ended

12 Months Ended

50 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Loss before income tax benefit

($15,077)

($11,642)

($18,625)

($15,519)

($13,319)

($21,774)

($19,188)

($8,258)

($60,863)

($62,539)

($35,544)

($173,974)

U.S. Operations [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Loss before income tax benefit

'

'

'

'

'

'

'

'

2,167

-13,834

-35,544

'

Foreign Operations [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Loss before income tax benefit

'

'

'

'

'

'

'

'

($63,030)

($48,705)

'

'

Income_Taxes_Reconciliation_Be

Income Taxes - Reconciliation Between Effective Tax Rate and Federal Statutory Rate (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Federal statutory rate	34.00%	35.00%	34.00%
States taxes, net of federal benefit	0.00%	0.00%	4.00%
Foreign rate differential	-9.00%	-8.00%	'
Permanent items-change in contingent consideration	-1.00%	-1.00%	-1.00%
Research and development credits	0.00%	1.00%	'
Advanced pricing agreement	-26.00%	'	'
Valuation allowance	'	-27.00%	-30.00%
Total effective tax rate and statutory rate	-2.00%	'	7.00%

Income_Taxes_Tax_Effects_of_Si

Income Taxes - Tax Effects of Significant Portions of Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Stock compensation	$1,948,000	$1,033,000
Professional fees	35,000	'
Net operating losses	'	12,176,000
Total deferred tax assets	1,983,000	13,209,000
Deferred tax liabilities:	'	'
Fixed assets	319,000	'
Total deferred tax liabilities	319,000	'
Valuation allowance	0	12,428,000
Net deferred tax assets	$1,664,000	$781,000

Income_Taxes_Net_Deferred_Tax_

Income Taxes - Net Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Current assets	$35	$781
Non-current assets	1,629	'
Net deferred tax assets	$1,664	$781

Income_Taxes_Schedule_of_Unrec

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Unrecognized tax benefits, Balance at December 31, 2012	$1,117
Unrecognized tax benefits, Increase related to prior year tax positions	242
Unrecognized tax benefits, Increase related to current year tax positions	18
Unrecognized tax benefits, Balance at December 31, 2013	$1,377

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
			NDA [Member]	Secondary Supplier Purchase Commitments [Member]	Purchase Commitments [Member]	Chicago, Illinois [Member]	Branford, Connecticut [Member]
Commitments And Contingencies [Line Items]	'	'	'	'	'	'	'
Purchase commitments associated with the three years	'	'	$6,000,000	$7,200,000	$29,100,000	'	'
Initial term of supply agreement, in year	'5 years	'	'	'	'	'	'
Renewal term of supply agreement, in year	'2 years	'	'	'	'	'	'
Expiration date of purchase agreement	12-Jun-17	'	'	'	'	'	'
Increase in purchase commitment amount	6,500,000	'	'	'	'	'	'
Amount of development fees incurred during the year	6,000,000	'	'	'	2,800,000	'	'
Cash paid for commitments purchased	3,367,000	5,844,000	'	'	800,000	'	'
Aggregate development fees required to be paid	1,700,000	'	'	'	'	'	'
Agreement expires period	'5 years	'	'	'	'	'	'
Rental fees	'	'	'	'	'	1,200,000	1,800,000
Amount of letter of credit on lease agreements	'	'	'	'	'	500,000	600,000
Rental fees, month term	'	'	'	'	'	'65 months	'62 months
Increased amount of letter of credit on lease agreement	'	'	'	'	'	'	$300,000

Commitments_and_Contingencies_2

Commitments and Contingencies - Minimum Aggregate Future Lease Commitments) (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2014	$576
2015	601
2016	608
2017	624
2018	127
Total future minimum payments	$2,536

Accrued_Expenses_Summary_of_Ac

Accrued Expenses - Summary of Accrued Expenses (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Contract research organizations	$1,360	$8,309
Contract manufacturers	2,746	540
Compensation and related benefits	2,279	1,428
Professional fees	87	141
Other expenses	644	184
Total accrued expenses	$7,116	$10,602

Accrued_Expenses_Summary_of_Ac1

Accrued Expenses - Summary of Accrued Expenses (Parenthetical) (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Manufacturing supplies	$1,768	'

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data - Summary of Selected Quarterly Financial Data (Detail) (USD $)	2 Months Ended	3 Months Ended								12 Months Ended				50 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2009	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013
Operating expenses:	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Research and development	'	$7,118	$5,928	$13,179	$11,092	$9,440	$18,956	$16,528	$6,771	$37,317	$51,695	$30,133	'	$124,161
General and administrative	'	5,215	4,823	4,514	4,050	3,622	2,552	2,392	1,221	18,602	9,788	4,305	'	36,384
Acquisition related charges, net	'	214	266	289	284	280	277	272	268	1,053	1,097	1,121	'	9,597
Operating loss	'	12,547	11,017	17,982	15,426	13,342	21,786	19,192	8,260	56,972	62,580	35,559	'	170,142
Other (income) expense, net	'	2,530	625	643	93	-23	-12	-4	-2	3,891	-41	-15	'	3,832
Loss before income taxes	'	15,077	11,642	18,625	15,519	13,319	21,774	19,188	8,258	60,863	62,539	35,544	'	173,974
Income tax expense	'	563	257	210	248	'	'	'	'	1,278	0	-2,511	'	-4,533
Net loss	($714)	($15,640)	($11,899)	($18,835)	($15,767)	($13,319)	($21,774)	($19,188)	($8,258)	($62,141)	($62,539)	($33,033)	($11,014)	($169,441)
Net loss per common share-Basic and Diluted	'	($0.59)	($0.45)	($0.75)	($0.86)	($0.73)	($1.47)	($260.25)	($132.12)	($2.57)	($7.48)	($551.51)	'	'
Weighted-average common shares-Basic and Diluted	'	26,623,724	26,620,497	25,169,543	18,367,540	18,359,667	14,781,419	73,727	62,500	24,224,590	8,364,432	59,896	'	'